Drainage implants safe for children

Article

Glaucoma drainage implant surgery is a safe and effective treatment for primary and secondary paediatric glaucoma in addition to initial surgical and medical therapy, according to Inka Helmanova and colleagues from the Masaryk University Hospital, Czech Republic.

Glaucoma drainage implant surgery is a safe and effective treatment for primary and secondary paediatric glaucoma in addition to initial surgical and medical therapy, according to Inka Helmanova and colleagues from the Masaryk University Hospital, Czech Republic.

Dr Helmanova conducted a retrospective study in 76 children undergoing glaucoma drainage implantation. Mean age was recorded at 6.9±5.3 years (range four months to 17.5 years). Results were compared for children with primary and secondary glaucoma. Mean follow-up was 7.1±6.5 years (range 1.6 to 15.2 years).

Mean preoperative and postoperative intraocular pressure (IOP) was 33.6±17.4 mmHg and 17.1±6.5 mmHg, respectively. Kaplan-Meier survival analysis demonstrated a cumulative probability of success of 93% at six months, 82% at two years, 71% at four years and 65% at six years. No differences were noted between primary (n=32 eyes) and secondary glaucoma (n=45 eyes) patients in terms of success (p=0.183), final IOP, number of medications or length of follow-up. Glaucoma drainage implant surgery was successful for a mean period of 6.7 years.

It would appear that glaucoma drainage implant surgery is both safe and effective as an addition to normal surgical treatment and medical therapy for paediatric patients.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.